You are here: Industry Insights > HSA

News List

Singapore HSA approves Pfizer-BioNTech’s shot for children Pharmaceutical-Technology
December 14, 2021
Singapore’s Health Sciences Authority (HSA) has approved the usage of Pfizer-BioNTech’s Covid-19 vaccine, Comirnaty, for the paediatric population of ages five to 11 years.
Cue Health Receives Singapore HSA Authorization for its Molecular COVID-19 Test for Self-Testing prnasia
December 02, 2021
Cue Health ("Cue") (Nasdaq: HLTH), a healthcare technology company, today announced it received Pandemic Special Access Route (PSAR) authorization from the Health Sciences Authority (HSA) for the Cue COVID-19...
Moderna’s Covid-19 vaccine receives interim authorisation in Singapore pharmaceutical-technology
February 05, 2021
The Singapore Health Sciences Authority (HSA) has approved the interim authorisation of Moderna’s mRNA Covid-19 vaccine for use under the Pandemic Special Access Route (PSAR).
LT1001 (Naldebain(R)), an Extended-Release Analgesic Injection, Received Its Second Approval from Singapore's HSA prnasia
December 23, 2020
Lumosa Therapeutics is pleased to announce the market approval of LT1001 (Naldebain®), an extended-release analgesic injection, from Singapore's Health Science Agency (HSA). HSA is regarded as one of the regulatory reference countries in the world.
World’s first migraine-specific prevention treatment available in Singapore biospectrumasia
November 26, 2018
Singapore – Novartis announced that the Health Sciences Authority (HSA) has approved Aimovig (erenumab) in Singapore for the prevention of migraine in adults.
ASLAN submits authorisation application with HSA biospectrumasia
July 04, 2018
The single ascending dose study will recruit healthy volunteers and the multiple ascending dose study will recruit patients with atopic dermatitis.